Daiichi Sankyo (DSNKY) Stock Price, News & Analysis

Company Overview

Daiichi Sankyo Co., Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies. Its broader portfolio includes Lixiana, also known as Savaysa in some markets, an oral anticoagulant based on edoxaban.

Daiichi Sankyo was formed in 2005 through the merger of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd., two established Japanese drugmakers. The company is headquartered in Tokyo and serves markets in Japan, North America, Europe and other international regions through its global research, manufacturing and commercial operations.

Key Stats

• Today's Range: $18.53 to $18.77
• 50-Day Range: $16.00 to $19.00
• 52-Week Range: $14.98 to $27.50
• Volume: 58,771 shs
• Average Volume: 87,813 shs
• Market Capitalization: $34.78 billion
• P/E Ratio: 21.71
• Dividend Yield: 1.82%
• Price Target: N/A
• Consensus Rating: Hold

Daiichi Sankyo Stock Analysis - MarketRank™

Daiichi Sankyo scored higher than 81% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Daiichi Sankyo has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Daiichi Sankyo has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 19.59%

Earnings Growth

Earnings for Daiichi Sankyo are expected to grow by 19.59% in the coming year, from $0.97 to $1.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Daiichi Sankyo is 21.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.64.

Price to Earnings Ratio vs. Sector

The P/E ratio of Daiichi Sankyo is 21.71, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.82.

Price to Earnings Growth Ratio

Daiichi Sankyo has a PEG Ratio of 2.56. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Daiichi Sankyo has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Daiichi Sankyo has been sold short.

Short Interest Ratio / Days to Cover

Daiichi Sankyo has a short interest ratio ("days to cover") of 0.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daiichi Sankyo has recently decreased by 15.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Daiichi Sankyo pays a meaningful dividend of 1.88%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Daiichi Sankyo does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Daiichi Sankyo is 39.53%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Daiichi Sankyo will have a dividend payout ratio of 29.31% next year. This indicates that Daiichi Sankyo will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.56

News Sentiment

Daiichi Sankyo has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Daiichi Sankyo this week, compared to 1 article on an average week.

Search Interest

1 people have searched for DSNKY on MarketBeat in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Daiichi Sankyo insiders have not sold or bought any company stock.

Percentage Held by Institutions

Daiichi Sankyo has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/31/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 10/30/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:DSNKY
• Previous Symbol: OTCMKTS:DSNKY
• CIK: N/A
• Web: www.daiichisankyo.com
• Phone: (136) 225-1111
• Fax: N/A
• Employees: 17,435
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): $0.86
• Trailing P/E Ratio: 21.71
• Forward P/E Ratio: 19.25
• P/E Growth: 2.56
• Net Income: $1.72 billion
• Net Margins: 10.92%
• Pretax Margin: 12.41%
• Return on Equity: 14.35%
• Return on Assets: 6.10%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 2.92
• Quick Ratio: 1.96

Sales & Book Value

• Annual Sales: $14.10 billion
• Price / Sales: 2.47
• Cash Flow: $1.18 per share
• Price / Cash Flow: 15.81
• Book Value: $5.80 per share
• Price / Book: 3.22

Miscellaneous

• Outstanding Shares: 1,862,893,000
• Free Float: N/A
• Market Cap: $34.78 billion
• Optionable: Not Optionable
• Beta: -0.11